Table 2.

Frequency of MBL deficiency-associated genotypes and MASP2 A/G heterozygosity

Group	C	NO	BT	OC G1-2	OC G3
n	172 (174)a	65 (67)a	107	33	63
MBL deficiency-associated genotypes (LXA/O + O/O) (%)	11.6	6.2	15	30.3b	12.7
MASP2 A/G heterozygotes (%)	8.6	7.5	9.3	24.2c	7.9
LXA/O + O/O (MBL2) and A/G (MASP2) (%)	0.6	0	0.9	12.1d	0

C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary ovarian cancer

^aNumbers of samples tested for D120G MASP2 polymorphism

^b p = 0.05 (vs OC G3); p = 0.01 (vs C); p = 0.04 (vs NO); p = 0.07 (vs BT)

^c p = 0.06 (vs OC G3); p = 0.02 (vs C); p = 0.03 (vs NO); p = 0.04 (vs BT)

^d p = 0.01 (vs OC G3); p = 0.002 (vs C); p = 0.01 (vs NO); p = 0.01 (vs BT)